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Background: There is resurgence within drug and biomarker development communities for the use of primary
tumorgraft models as improved predictors of patient tumor response to novel therapeutic strategies. Despite
perceived advantages over cell line derived xenograft models, there is limited data comparing the genotype and
phenotype of tumorgrafts to the donor patient tumor, limiting the determination of molecular relevance of the
tumorgraft model. This report directly compares the genomic characteristics of patient tumors and the derived
tumorgraft models, including gene expression, and oncogenic mutation status.
Methods: Fresh tumor tissues from 182 cancer patients were implanted subcutaneously into immune-
compromised mice for the development of primary patient tumorgraft models. Histological assessment was
performed on both patient tumors and the resulting tumorgraft models. Somatic mutations in key oncogenes and
gene expression levels of resulting tumorgrafts were compared to the matched patient tumors using the
OncoCarta (Sequenom, San Diego, CA) and human gene microarray (Affymetrix, Santa Clara, CA) platforms
respectively. The genomic stability of the established tumorgrafts was assessed across serial in vivo generations in a
representative subset of models. The genomes of patient tumors that formed tumorgrafts were compared to those
that did not to identify the possible molecular basis to successful engraftment or rejection.
Results: Fresh tumor tissues from 182 cancer patients were implanted into immune-compromised mice with
forty-nine tumorgraft models that have been successfully established, exhibiting strong histological and genomic
fidelity to the originating patient tumors. Comparison of the transcriptomes and oncogenic mutations between the
tumorgrafts and the matched patient tumors were found to be stable across four tumorgraft generations. Not only
did the various tumors retain the differentiation pattern, but supporting stromal elements were preserved. Those
genes down-regulated specifically in tumorgrafts were enriched in biological pathways involved in host immune
response, consistent with the immune deficiency status of the host. Patient tumors that successfully formed
tumorgrafts were enriched for cell signaling, cell cycle, and cytoskeleton pathways and exhibited evidence of
reduced immunogenicity.
Conclusions: The preservation of the patient’s tumor genomic profile and tumor microenvironment supports the
view that primary patient tumorgrafts provide a relevant model to support the translation of new therapeutic
strategies and personalized medicine approaches in oncology.
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Although direct transfer xenografts of fresh human
tumors, or primary “tumorgrafts”, have been reported
as early as the 1970s for testing of new pharmaceut-
ical agents [1-4], only recently has there been a resur-
gence of interest in this alternative to the more
traditional cell line xenograft models. This has been
due, in part, to the growing realization that drugs
which work in the traditional cell line xenograft mod-
els rarely exhibit comparable efficacy in patients with
the anatomically/pathologically equivalent tumor [5-7].
Indeed, it has been highlighted that the failure of
drugs during clinical trials is linked to a lack of test-
ing in clinically relevant preclinical models [8]. The
advent of “precision medicine” (PMed), utilizing novel
molecular techniques to design patient tumor-specific
therapeutic regimens, requires preclinical cancer mod-
els that closely reflect the originating human disease
to allow evaluation and rapid translation of these mo-
lecular based approaches to therapy selection in the
clinic [9].
While there have been a growing number of studies
reporting comparative chemotherapeutic responses be-
tween tumorgraft models and patients [10-13], there is
limited data addressing genomic similarities between
tumorgraft models and the originating patient tumors
[14-16]. Previous studies have reported excellent con-
cordance in expression profiles between patient tumors
and tumorgraft models of similar histotypes [17,18];
however, the comparisons were not made in a pairwise
fashion between each tumorgraft and the originating
tumor from the donor patient.
Given the added cost and time required to develop
primary patient tumorgrafts relative to the more clas-
sical cell line xenografts, a detailed cellular and mo-
lecular characterization of the tumorgraft models
showing a high degree of equivalence to the originat-
ing patient’s tumor in the human host could provide
the justification for the routine use of this model,
even at the ectopic subcutaneous site, in translational
studies and personalized medicine applications. Our
goal was to compare the genomic profiles of a panel
of diverse tumorgraft models to the patient tumor tis-
sue from which the models were derived. To address
inter-disease variability, the panel of tumorgraft mod-
els selected for this study contains a spectrum of neo-
plastic diseases, rather than a limited set of disease
types [14-16,19]. Our long term objective is to de-
velop this panel of mixed-type tumorgraft models to
evaluate new treatment strategies based on the mo-
lecular characterization of an individual disease and
the subsequent treatment with targeted therapy, inde-
pendent of the tumor histology and anatomical
location.Methods
Human subjects
Ethical approval for this study was granted by the Insti-
tutional Review Boards at both the Van Andel Research
Institute (VARI) and the collaborating clinical institu-
tions: Spectrum Health Hospitals, Grand Rapids, MI;
Saint Mary's Health Care, Grand Rapids, MI; Oncology
Care Associates, St. Joseph, MI; Mary Crowley Cancer
Research Centers, Dallas, TX. Written, informed consent
was obtained from each patient or guardian prior to
study enrollment. Eligibility for tumorgraft development
was not limited by cancer type, cancer staging, or ana-
tomical location. The tumor tissue used for tumorgraft
development was deemed excess to that required for the
patient’s diagnosis and standard of care and treatment.Tumor processing
The tumor tissue was subdivided into a portion for gen-
omic analysis and a portion for implantation into
immune-compromised mice. Tissue for genomic analysis
was snap frozen (30–60 s) in chilled isopentane (dry ice)
and stored at −80° C. Tumor tissue for implantation into
mice was maintained in 6 ml transport media, [RPMI
1640 media (Invitrogen, Carlsbad, CA), 1% penicillin/
streptomycin (Invitrogen), and 50 units of heparin
(Sigma, St. Louis, MO)/ml media] at 4 °C until implant-
ation. Samples from distant sites were shipped on wet
ice and were implanted within 24 hours of surgical
resection.Tumorgraft development
All animal studies were approved by the VARI Institu-
tional Animal Care and Use Committee (IACUC) and
used 6–8 week old athymic nu/nu mice from the VARI
breeding colony. Food and water was available ad libi-
tum for the duration of the studies. Mice for each
tumorgraft model were gender matched to the donor pa-
tient. Body weights of the mice were recorded weekly
during tumorgraft development. Tumorgraft volumes
(½ x length x depth x height) were measured 1x/week
when volumes ≤50 mm3 and 3x/week at tumor vol-
ume >50 mm3. Mice were euthanized and subcutane-
ous tumorgrafts harvested following IACUC guidelines.
Upon receipt, the tumor tissue for implantation was
placed into a sterile dish containing sterile phosphate
buffered saline (Invitrogen) and carefully teased into ≤3
millimeters (longest axis) tumor fragments. Dependent
on tumor tissue availability, tumor fragments were
implanted in a maximum of five mice (1st generation).
Following administration of general anaesthesia (isoflur-
ane), the right flank was cleaned with 70% ethyl alcohol,
a small incision made, and a subcutaneous pocket cre-
ated by blunt dissection. The tumor fragment was
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surgical staple. Immediately following surgery, the
mouse received a single dose of the analgesic Ketoprofen
(5 mg/kg body weight). Mice were monitored for health
and tumor growth for the duration of the study. A
tumorgraft model that failed to develop within 6 months
in the 1st generation mice was discontinued and the
mice euthanized.
When a 1st generation tumorgraft reached a volume
of ≥1500 mm3 the mouse was euthanized and the
tumorgraft was aseptically harvested. The tumorgraft
was subsequently divided into pieces for four applica-
tions: 1) 5 pieces (≤3 millimeters (longest axis) were
directly transplanted into 2nd generation mice; 2) 18
pieces (≤3 millimeters (longest axis) were cryopre-
served (RPMI 1640 media (Invitrogen), 10% fetal bo-
vine serum (Invitrogen), 10% dimethyl sulfoxide
(Sigma, St. Louis, MO), and 50 units heparin (Sigma)/ml
RPMI 1640 media), using a “Mr. Frosty” Freezing Con-
tainer (Thermo Scientific, Waltham, MA) at −1°/min
cooling rate, in a −80 °C freezer, to allow for subsequent
reestablishment of the tumorgraft model; 3) a single
piece (3 mm x 5 mm x 5 mm) was snap frozen for future
genomic/proteomic analysis; and 4) remaining tissue was
formalin fixed.
The 2nd generation mice were monitored for health
and tumorgraft growth characteristics as with the 1st
generation mice. Once a total of ~50 tumorgraft frag-
ments, from either 1st or 2nd generation mice, had been
cryopreserved, all remaining mice were euthanized and
any tumorgrafts harvested (snap frozen and formalin
fixed) and stored for subsequent analyses. Two osteosar-
coma models were grown out to a 4th generation and
used to examine longitudinal changes such as genetic
drift and mutation status.
For a tumorgraft model to be considered fully estab-
lished the following three criteria needed to be met: 1)
1st generation growth, 2) 2nd generation tumor growth
following direct (fresh) transplant of a tumor fragment
from a 1st generation mouse, and 3) re-growth of the
cryopreserved tumor fragment. To test cryo-viability,
three 1st generation tumor fragments, frozen in liquid
nitrogen for a minimum of four weeks, were thawed
rapidly, rinsed in sterile phosphate buffered saline
(Invitrogen) containing 1% penicillin/streptomycin
(Invitrogen), and implanted into immune-compromised
mice, as described above. In the event that the cryo-
preserved tissue failed to develop into a tumorgraft
within 6 months, the model was deemed unsuccessful
and the mice euthanized. While the preservation of
the histopathological features of the primary patient
tumor in the resulting tumorgraft models was assessed,
it was not a requirement for a successful model
development.Data storage and management
For this study, all clinical, preclinical, histological,
and genomic data was stored and analyzed using
the XenoBase-BioIntegration Suite (XB-BIS) (http://
xbtransmed.com/). Data analysis is accomplished by in-
tegrating molecular, preclinical and clinical data, facili-
tating integrated analysis within this single platform as
described in the pertinent sections below.
Histological analysis of tumorgrafts and patient tumors
Histopathological evaluation was performed on five mi-
cron hematoxylin and eosin (H&E) stained sections of
formalin-fixed paraffin-embedded (FFPE) pieces of pa-
tient tumors and of subsequent 1st and 2nd generation
tumorgrafts. Tissue sections were reviewed by two inde-
pendent pathologists (BJN & RS) to compare the patho-
logical features of the tumorgrafts and compared
directly with those of the corresponding patient tumor.
Mutational analysis using the sequenom OncoCarta assay
For mutation detection, the OncoCarta mutation panel
was used according to manufacturer’s protocol (Seque-
nom, San Diego, CA). The OncoCarta™ Panel v1.0
(Sequenom, San Diego, CA) has the capacity to detect
238 mutations in 19 oncogenes.
Ten representative pairs of 1st generation tumorgrafts
and originating patient tumors and 1st - 4th generation
series of an osteosarcoma tumorgraft model were
screened using the MassARRAY system and OncoCarta
Panel v1.0 (Sequenom, San Diego, CA) [20,21]. Tumor
DNA was isolated from either snap frozen of formalin-
fixed paraffin embedded tissue using an initial Proteinase
K digestion followed by salt ethanol precipitation. The
DNA was further purified using the QIAamp DNA
micro Kit (Qiagen, Valencia, CA). Only samples in which
the H&E sections, from above and below the processed
tissue, contained ≥50% of viable malignant cell content
(assessed by nuclei vs. surface area) were submitted for
analysis of oncogenic mutations.
The spectra from the MassARRAY Compact Analyzer
were loaded into MassARRAY Typer Analyzer software
4.0.4.20 (Sequenom). The analysis software automates
the identification of mutants by comparing ratios of the
wild type peak to that of all suspected mutants and
adjusting these peaks for adducts it detects in the
spectrum [20,21]. All mutations detected by this auto-
mated process were visually reviewed to identify "real"
mutant peaks and to remove all artifact peaks due to salt
peaks or other background peaks.
Gene expression analysis
Transcriptome profiling of the genomes of 24 represen-
tative 1st generation tumorgraft/patient tumor pairs,
encompassing gastrointestinal, musculoskeletal, skin,
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of two musculoskeletal models across four tumorgraft
generations was performed using the Human U133 Plus
2.0 GeneChipW (Affymetrix, Inc, Santa Clara, CA). The
resulting gene expression data were stored and analyzed
in XB-BIS. RNA was isolated from snap-frozen patient
tumors and tumorgraft tissue that was assessed for vi-
able malignant cell content, as described above.
RNA was isolated by chloroform extraction, precipita-
tion in isopropyl alcohol, a 70% ethanol wash and sus-
pension in nuclease free water. A final RNA purification
was performed using RNeasy Mini-/Micro-KitTM (Qia-
gen) with an on-column DNase 1 digestion. RNA quan-
tity and purity was determined using a NanoDrop
Spectrophotometer (NanoDrop, Wilmington, DE); RNA
quality was determined with an Agilent 2100 Bioanalyzer
(Agilent, Foster City, CA).
Labeled one round cDNA was generated either by the
Affymetrix method: Gene-Chip One-Cycle Target Label-
ing and Control Reagent (Affymetrix) or by the NuGEN
method: WT-Ovation Pico RNA Amplification system
and FL-Ovation cDNA Biotin Module (NuGEN Tech-
nologies, Inc., San Carlos, CA). The resulting amplifica-
tion products were quantified and hybridized to
GeneChipW Human Genome U133 Plus 2.0 Arrays
(Affymetrix, Inc). Hybridization, washing, staining and
scanning of the arrays were performed according to
manufacturer’s instructions (Affymetrix, Inc.). The
resulting .cel files were loaded into the Affymetrix Ex-
pression Console Version 1.1, batch processed using the
Affymetrix MAS5 algorithm with a target value of 500.
The resulting pivot table of normalized expression inten-
sities was then exported into XB-BIS for subsequent
analysis.
Comparative analysis of genomes of tumorgrafts and
matched patient tumors
Genomic similarity between the tumorgraft and its
matched patient tumor were assessed by determination
of Pearson correlation coefficients and by unsupervised
cluster analysis. For determination of Pearson correl-
ation coefficients, gene expression data was filtered to
remove those Affymetrix probes deemed absent and/or
with normalized intensities less than 100 in ≥50% of the
sample set of 24 matched tumor/tumorgraft pairs
(n = 25,806 probe sets); the gene expression data was not
censored for Affymetrix x_at probes.
For unsupervised cluster analysis, the selection of the
significant variance probes was made to emphasize the
differences in the matched tumor pairs, which is dimin-
ished by large numbers of low intensity, non-significant
probes that are similar both between pairs and across
the tumor panel. The probe sets were filtered to include
only probe sets with an intensity ≥150, called present in≥20% samples, and exhibited significant variance (coeffi-
cient of variance >1). Affymetrix x_at probes were
excluded from the final data used for the cluster
analysis.
Initial unsupervised clustering of the 24 tumorgraft/
patient tumors, identified that the choice of RNA amplifi-
cation methods, Affymetrix and NuGEN, was a significant
confounding variable (data not shown). Subsequently, the
48 data sets were clustered independently, based on
method of RNA amplification (Affymetrix, 28 genomes;
NuGEN, 20 genomes). The resulting Affymetrix amplifi-
cation probe set (n = 6,845) and NuGEN amplification
probe set (n = 6,265) were loaded into the programming
language R version 2.11.1. The distance matrix was cre-
ated using Euclidean distance default parameters and
complete linkage with the default parameters were uti-
lized for the hclust function. The unrooted dendrogram
was constructed using the phylo object and plotted with
default parameters.
To determine whether the differential expression in
the genomes between the tumorgrafts and the originat-
ing patient tumors was random or represent a gain or
loss of specific pathways, a paired t-test (p< 0.05) was
employed on the set of 25,806 probes, generated above,
to identify those genes that were differentially expressed,
2-fold or greater, between tumorgrafts and their
matched tumors. No multiple testing correction was ap-
plied because the sequential pathway enrichment ana-
lysis is expected to remove or diminish the effects of
random significant gene selection. The resulting genes
up-regulated (n = 17) or down-regulated (n = 395) in
tumorgrafts, as compared to the originating patient
tumors (Additional file 1: Table S1), were analyzed for
canonical pathway enrichment and ontology enrichment
using the MetaCore™ pathway analysis suite (GeneGo-
Thomson Reuters, St. Joseph, MI) using p-values of
hypergeometric distribution as enrichment and ranking
method [22]. GeneGo’s data import methods automatic-
ally resolve duplicate gene mapping and unmapped Affy-
metrix probes. The attrition in the mapping of the
Affymetrix probes in Additional file 1: Table S1 ranged
from 30% to 35%. In addition, the gene lists were ana-
lyzed for enrichment in broadly defined protein func-
tions, i.e. transcription factors, secreted proteins,
kinases, receptors, proteases, etc. using MetaCore™’s
Interactome workflow.
Analysis of genomes of tumors that successfully formed
tumorgrafts compared to tumors that failed to
form tumorgrafts
To begin to understand why all donor tumors do not
form tumorgrafts following transplant into immune-
compromised mice, the genomes of 16 patient tumors
that did form tumorgrafts were compared to 16 tumors
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selected since they were all amplified by the Affymetrix
method, thus removing the confounding effect of the
RNA amplification method.
For the analysis of the tumorgraft-forming tumor gen-
omes against the non-tumorgraft forming tumor gen-
omes, a student’s two-tailed t-test (p< 0.05) was
employed to identify genes that were differentially
expressed, 2-fold or greater, between the two classes. No
multiple testing correction was applied because the se-
quential pathway enrichment analysis is expected to re-
move or diminish the effects of random significant gene
selection. The resulting list of up-regulated (n = 491) and
down-regulated (n = 691) genes in the tumorgraft-
forming tumors, compared to the non-tumorgraft form-
ing tumors (Additional file 2: Table S2), were submitted
to MetaCore™ for enrichment analysis and interaction
analysis, as described above. The attrition in the map-
ping of the Affymetrix probes in Additional file 2: Table
S2 ranged from 28% to 36%.
Results
Forty-nine tumorgraft models, representing 18 distinct
cancer pathologies have been developed by direct im-
plantation of patient tumor tissue into immune-
compromised nude mice giving the overall take rate of
27% (Table 1). These 49 models were distributed across
eight different cancer location categories, based on the
NCI Cancer by Body Location/System (Table 2). Tumor-
graft models of the gastrointestinal tract and skin ac-
count for ~50% of successfully established tumorgraft
models. There were an additional three models that
formed 1st generation tumorgrafts but that failed to re-
establish tumorgrafts following cryopreservation of 1st
generation tumorgraft fragments, giving a 94% success
rate in tumorgraft model re-establishment following
cryopreservation. No association was identified between
tumorgraft development and the time between surgical
resection and implantation (p = 0.86 by simple t-test on
representative sample set, data not shown).
The take rate (the ability of donor tumor to success-
fully be propagated in mice) was closely related to tumor
stage at time of resection. Forty-three percent (35/82) of
tumors with a pathological staging of Stage III and Stage
IV tumors were successfully propagated in mice,
accounting for 73% of fully developed models (Table 2).
Only 10% (6/60) of the donor tumors from Stage I or II
cancers successfully propagated formed tumorgrafts in
mice, accounting for only 12% of the fully developed
models. Pathological staging information for the
remaining 22% of the tumor tissues implanted into mice
(40/182) which formed tumorgrafts was not obtained. A
contingency table analysis with stage III and IV as one
condition and stage I and II the second conditionsupported the hypothesis with a p-value = 1.2 E-5 and an
odds ratio of 6.7 for this data set (data not shown).
Tumorgraft development was also found to be related
to cancer type. Of the human tumor samples used to de-
rive the panel of 49 tumorgraft models, a success rate of
>40% was observed for skin (65%), musculoskeletal
(54%), head and neck cancers (50%), and gastrointestinal
cancers (41%) (Table 1). Lung (26%), genitourinary
(22%), and endocrine (20%) cancers exhibited lower take
rates for tumorgraft formation. Cancers of the breast
(5%), predominantly early stage (data not shown), and
the lymphatic system (0%) proved the most challenging
to form tumorgrafts using the athymic nude mouse
strain and methodologies adopted here. No tumorgrafts
were established from tumors of gynecologic, leukemic,
or neurologic origins; however, these finding are not ne-
cessarily representative of the true take rate for these
tumor types as ≤2 attempts for each of these cancer
types were attempted.
Hematoxylin and eosin stained sections from matching
patient tumors and 1st and 2nd generation tumorgrafts
from pancreatic cancer, breast cancer, lung cancer and
cervical cancer models were examined for histological
similarities. In all 4 different tumorgraft models, the ini-
tial patient tumors were characterized by histological
features consistent with the anatomical site of origin
(Figure 1 A-D). The 1st generation tumor grafts
resembled the original patient tumor, including in most
instances retention of peritumoral stroma which became
progressively replaced in the 2nd generation tumorgrafts
by malignant cell overgrowth. In addition, the relative
state of differentiation of the respective cancer type was
retained following engraftment, including production of
mucin and retention of atypical glandular structures for
the adenocarcinomas, even after 302 and 177 days for
the pancreatic and breast cancers, respectively. In the
lung cancer and cervical cancer models, the 1st and 2nd
generation tumors revealed viable malignant appearing
cells. The 2nd generation tumorgrafts retained essential
diagnostic features at 286 and 345 days, respectively, for
the lung and cervical cancer models.
Of the 20 samples (10 patient samples, 10 1st gener-
ation tumorgraft samples) submitted for oncogene muta-
tion analysis, only 15 mutations were identified. Four
tumorgraft models each had a single point mutation that
was also observed in the originating tumor tissue. Mod-
els VARI-LTM-044 colorectal cancer and VARI-LTM-
034 pancreatic cancer both had a single KRAS mutation;
melanoma models VARI-LTM-086 and VARI-LTM-027
had BRAF and NRAS mutations, respectively (Table 3).
Model VARI-LTM-041 colorectal cancer contained three
mutations (KRAS and two PIK3CA mutations) that were
also present in the matching tumor. The colorectal can-
cer model VARI-LTM-026, did not exhibit mutations in
Table 1 Summary of Tumorgraft Development
Location Tumor type # Models Success Failure Success (%)
Breast Breast Cancer 55 3 52 5
Total 55 3 52 5
Endocrine Neuroendocrine Tumor 3 1 2 33
Papillary Thyroid Carcinoma 2 0 2 0
Total 5 1 4 20
Gastrointestinal Cecal Adenocarcinoma 1 1 0 100
Cholangiocarcinoma 1 0 1 0
Colorectal Cancer 17 8 9 47
Esophageal Adenocarcinoma 5 2 3 40
Gallbladder Carcinoma 1 0 1 0
Gastric Carcinoma 3 1 2 33
Hepatoblastoma 1 0 1 0
Pancreatic Cancer 6 3 3 50
Small Bowel Cancer 2 0 2 0
Total 37 15 22 41
Genitourinary Bladder Carcinoma 1 0 1 0
Clear Cell Sarcoma 1 0 1 0
Prostate Adenocarcinoma 1 0 1 0
Renal Cell Carcinoma 4 0 4 0
Urachal Adenocarcinoma 1 1 0 100
Wilms Tumor 1 1 0 100
Total 9 2 7 22
Gynecologic Ovarian Carcinoma 2 0 2 0
Total 2 0 2 0
Head and Neck Head and Neck Cancer 2 2 0 100
Nasopharyngeal Cancer 1 0 1 0
Squamous Cell Carcinoma of the mouth 1 0 1 0
Total 4 2 2 50
Leukemia Acute Lymphoblastic Leukemia 1 0 1 0
Total 1 0 1 0
Lung Squamous Cell Carcinoma of the lung 5 0 5 0
Lung Adenocarcinoma 4 1 3 25
Small Cell Lung Cancer 1 0 1 0
NSCLC 13 5 8 38
Total 23 6 17 26
Lymphoma Burkitts Lymphoma 1 0 1 0
Follicular Lymphoma 3 0 3 0
Hodgkins Lymphoma 1 0 1 0
Lymphoangioma 1 0 1 0
Lymphoma 6 0 6 0
Total 12 0 12 0
Musculoskeletal Desmoid Tumor 1 0 1 0
Ewings Sarcoma 3 2 1 67
Hemangiopericytoma 1 0 1 0
Leiomysarcoma 1 0 1 0
Monsma et al. Journal of Translational Medicine 2012, 10:125 Page 6 of 18
http://www.translational-medicine.com/content/10/1/125
Table 1 Summary of Tumorgraft Development (Continued)
Osteosarcoma 3 3 0 100
Rhabdomyosarcoma 3 1 2 33
Synovial Sarcoma 1 1 0 100
Total 13 7 6 54
Neurologic Neuroblastoma 1 0 1 0
Total 1 0 1 0
Skin Melanoma 18 11 7 61
Merkel Cell Carcinoma 2 2 0 100
Total 20 13 7 65
Final Total 182 49 133 27
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in the tumorgraft. In the osteosarcoma model VARI-
LTM-021, no mutations were identified in the patient
tumor with any genetic drift identified in the 1st - 4th
generation tumorgrafts (data not shown).
Paired analysis of the 24 tumorgraft/tumor pairs
exhibited a high degree of similarity, with Pearson cor-
relation coefficients ranging from r = 0.75 to 0.99 with a
median coefficient of 0.93 (Table 4). There were only
four pairs, three gastrointestinal and one lung, that had
Pearson values r< 0.90; the NSCLC model VARI-LTM-
023 had the Pearson correlation coefficient of r = 0.75.Table 2 Distribution of Tumorgraft Models across Cancer Loc
Location Tumor type # Mod
Breast Breast Cancer 3
Endocrine Neuroendocrine Tumor 1





Genitourinary Wilms Tumor 1
Urachal Adenocarcinoma 1
Head and Neck Head and Neck Cancer 2
Lung Lung Carcinoma 1
NSCLC 5





Merkel Cell Carcinoma 2
Total 49For this model, the originating patient tumor RNA had a
RIN (RNA Integrity Number) of 4.9 implying degraded
RNA, which was likely to be the primary factor driving
the low correlation and would typically be excluded
from the molecular analysis.
Of the 28 genomes amplified by the Affymetrix
method, 12 of the 14 tumorgraft/donor tumor pairs co-
clustered in an unsupervised analysis (Figure 2A). Of the
20 genomes amplified by the NuGEN method, 7 of 10
tumorgraft/ tumor pairs coclustered (Figure 2B). 4 of the
5 tumorgraft/tumor pairs that did not co-cluster in
an unsupervised fashion exhibited Pearson correlationation Categories and Staging
els Staging



















Figure 1 Histological resemblance between patient tumor and resulting tumorgraft following sequential grafting into
immunocompromised mice. Representative sections stained with hematoxylin and eosin of indicated tumor samples (Scale bars indicate
100 μm). A) Adenocarcinoma of pancreas with desmoplastic stromal reaction in original patient tumor. 1st generation tumorgraft (total time
in vivo, 217 days) with preservation of atypical glandular structures with inspissated mucinous material surrounded by fibrous stroma. 2nd
generation tumorgraft (303 days) with similar histology. B) Adenocarcinoma of colon with numerous atypical glands containing mucinous
material and necrotic debris with surrounding fibrovascular connective tissue. 1st generation tumorgraft after 101 days reveals dilated atypical
ducts with mucin and necrotic debris in lumens comprised of multiple columnar layers of atypical epithelium surrounded by fibrovascular stroma.
2nd generation graft after 177 days with similar histology. C) Lung carcinoma with prominent fibrovascular connective tissue in original patient
neoplasm that becomes progressively overgrown by malignant cells in 1st (216 days) and 2nd (286 days) generation tumor grafts. D) Cervical
carcinoma with fibromucinous stroma in original patient neoplasm, with expansion of large islands of malignant cells surrounded by fibrovascular
stroma in 1st (282 days) and 2nd (345 days) generation tumorgrafts.
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ating patient tumor from the NSCLC model VARI-LTM-
023 co-clustered despite a low Pearson correlation
coefficient of r = 0.75, suggesting significant variance in
respect to other tumors in the cohort.Table 3 Oncogene mutations detected in tumorgrafts and ori
Model Tumor Type Gene Mutation
VARI-LTM-041 Colorectal Cancer KRAS G12V
VARI-LTM-041 Colorectal Cancer PIK3CA R88Q
VARI-LTM-041 Colorectal Cancer PIK3CA E545K
VARI-LTM-044 Cecal Adenocarcinoma KRAS G13D
VARI-LTM-026 Colorectal Cancer KRAS G12D
VARI-LTM-086 Melanoma BRAF V600E
VARI-LTM-027 Melanoma NRAS Q61R
VARI-LTM-034 Pancreatic Cancer KRAS Q61HThe genomic profiles of two representative osteosar-
coma models VARI-LTM-020 and VARI-LTM-021 were
observed over 4 generations to assess the potential for
genomic drift over time in vivo. The Pearson correlation
coefficients were very high, ranging from r = 0.98-0.99ginating patient tumors









Table 4 Pearson correlation coefficient of each individual tumorgraft and originating patient tumor based on
Affymetrix gene expression data
Cancer Location Category Tumor Type Subject ID Pearson correlation (R)
Gastrointestinal Cecal Adenocarcinoma VARI-LTM-044 0.87
Colorectal Cancer VARI-LTM-026 0.86
Colorectal Cancer VARI-LTM-034 0.97
Colorectal Cancer VARI-LTM-041 0.99
Gastric Carcinoma VARI-LTM-024 0.86
Pancreatic Cancer VARI-LTM-035 0.92
Genitourinary Wilms Tumor VARI-LTM-022 0.98
Head and Neck Head and Neck Cancer VARI-LTM-042 0.94
Head and Neck Cancer VARI-LTM-045 0.90









Synovial Sarcoma VARI-LTM-019 0.91
Skin Melanoma VARI-LTM-025 0.96
Melanoma VARI-LTM-027 0.92
Melanoma VARI-LTM-043 0.97
Merkel Cell Carcinoma VARI-LTM-033 0.97
Merkel Cell Carcinoma VARI-LTM-039 0.93
Monsma et al. Journal of Translational Medicine 2012, 10:125 Page 9 of 18
http://www.translational-medicine.com/content/10/1/125between all 4 generations in both models (data not
shown). The largest decrease in Pearson correlation co-
efficient occurred between the human tumor to 1st gen-
eration mouse tumorgraft (VARI-LTM-020, r = 0.91;
VARI-LTM-021, r = 0.94). Genomic fidelity was then
maintained in subsequent mouse to mouse generation
comparisons. This stability in the genomes across mouse
tumorgraft generations, along with the absence of add-
itional somatic oncogene mutations suggests the main-
tenance of genomic stability during serial in vivo
passages and time in vivo for at least up to 186 days
(VARI-LTM-021).
Paired analysis of all 24 tumorgrafts to their matching
tumors identified 25,806 gene probes that were present
in at least 50% of the 48 samples. 395 genes were
decreased and 17 genes increased two-fold or greater in
the tumorgrafts (Additional file 1: Table S1) compared
to the patient tumors (Figure 3A, green and red circles
respectively).
Of the 395 genes down-regulated in the murine
tumorgrafts, there was a significant enrichment in
pathways related to immune response (Figure 3B). En-
richment scores were extremely high, with the top-scored classical complement pathway showing a –log
p-value of 25. Of the 17 genes up-regulated in the
tumorgrafts, there were only 1–2 genes per map, sug-
gesting no enrichment for any canonical pathway
(data not shown). An independent GO biological
pathway enrichment analysis was conducted using the
down regulated probe list and 14 of the most signifi-
cantly enriched top 100 pathways p< 4.0E-9 were
associated with immune response [23]. Classification
of the down-regulated genes with regards to enrich-
ment in protein function, identified a borderline sig-
nificance (p = 0.05) in receptors and ligands in the
tumorgrafts compared to the patient tumors. For the
up-regulated genes, the only significant enrichment in
protein function was for proteases, accounting for
only two of the 17 genes.
Comparative analysis of the patient tumors that
formed tumorgrafts to patient tumors that did not form
tumorgrafts identified 491 genes that were up-regulated
and 691 genes down-regulated 2-fold or greater in those
tumors that formed tumorgrafts compared to non-
tumorgraft forming tumors (Additional file 2: Table S2).
The up-regulated genes in the tumors that formed
Figure 2 Unsupervised cluster analysis of genomes of tumorgrafts and originating patient tumors. Unsupervised clustering was
performed on genomes amplified by A) Affymetrix method, 28 genomes total; and B) NuGEN method, 20 genomes total. Clustering was
performed using programming language R version 2.11.1 on normalized gene expression data that was pre-processed using the Affymetrix MAS5
algorithm to an average intensity target of 500. Other than a few highlighted outliers discussed in the text, patient tumors and their derived
tumorgrafts are closely related at the gene expression level.
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pathways and cytoskeleton remodeling (Figure 4A). One
key canonical pathway map, enriched with up-regulated
genes that were elevated in those tumors that formed
tumorgrafts, is for WNT signaling (Figure 5); genes up-
regulated in this pathway map included VEGF-A,
Frizzled, β-Catenin, c-Myc, and FAK-1. The down-
regulated genes in the tumorgraft-forming tumors were
enriched for immune response pathways (8/10 pathways,
Figure 4B). One key pathway map enriched with down-regulated genes is that of the role of integrins in NK cell
cytotoxicity (Figure 6); note that in the context of this
study, the upper Target Cell in this pathway corresponds
to the relevant tumorgraft-forming cells.
Discussion
The goal of this study was to create a panel of tumor-
graft models, developed directly from patient tumor tis-
sue from a wide range of heterogeneous tumor types of
various stages. Prior investigations have focused on
Figure 3 Enrichment of canonical pathway maps in genes downregulated in tumorgrafts compared to their donor tumors. A) Scatter
plot of expression of gene probes (25,806) graphically depicting the up-regulated (red circle) and down-regulated (green circle) 2-fold or greater
(t-test, p≤ 0.05) in tumorgrafts relative to the originating patient tumors. B) Ontology enrichment analysis was performed using the MetaCore™
pathway analysis suite (GeneGo-Thomson Reuters, St. Joseph, MI). Eight of the top ten canonical pathways enriched in the genes down-regulated
in the tumorgrafts, relative to the originating patient tumors, were immune-related, consistent with immunodeficient status of the murine host.
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[24], pancreatic cancer [16], pediatric osteosarcomas
[14], or pediatric rhabdomyosarcoma [25], rather than a
spectrum of malignancies. To examine the suitability of
the panel of tumorgraft models generated in our lab as
molecularly-relevant preclinical models, we directly
compared a number of phenotypic and genotypic fea-
tures of the tumorgrafts to the originating patient
tumors from which they were derived.We have fully developed 49 models, spanning 18 dif-
ferent cancer types. A critical component of our devel-
opment process is the ability of the model to re-establish
following cryopreservation, alleviating the need for con-
tinual propagation, reported by some investigators [16].
Cryopreservation significantly reduces the cost and ne-
cessary resources, extending the life of the tumor model,
and minimizing genetic drift that could occur following
long-term continuous in vivo propagation.
Figure 4 Enrichment of canonical pathway maps in genes up and downregulated in tumorgraft forming tumors compared to
non-tumorgraft forming tumors. Ontology enrichment analysis was performed using the MetaCore™ pathway analysis suite (GeneGo-Thomson
Reuters, St. Joseph, MI). A) The top ten canonical pathway maps enriched in the genes up-regulated (n = 491) in the tumors that formed
tumorgrafts included cell signalling and cell cycle-related pathways. B) Eight of top ten canonical pathway maps enriched in the genes
down-regulated (n = 691) in the tumorgrafts that formed tumorgrafts were immune-related pathways.
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reports [3,5]. A number of strategies have been tested to
improve tumorgraft take rates, including the severe
combined immunodeficient mouse strains CB17SC-M-F
scid−/− [9,25,26] and CB17/Icr scid [12], suppression of
the immune system of recipient CBA/CaJ mice by thym-
ectomy, whole body irradiation, administration of 1-β-
D-arabinofuranosylcytosine [14,25], and use of orthotopicmodels [27]. However, these strategies could increase the
cost of model development with minimal improvement in
tumorgraft development over the use of subcutaneous
implantation into naive athymic nu/nu mice reported in
this study and by other investigators [2,16].
It should be noted use of the athymic nu/nu mouse
for use in the development of such tumorgraft does have
limitations. The use of more immunodeficient mouse
Figure 5 WNT signalling pathway map enriched with genes up-regulated in tumorgraft-forming tumors. The MetaCore™ pathway
analysis suite (GeneGo-Thomson Reuters, St. Joseph, MI) identified a pathway map for WNT signalling. VEGF-A, Frizzled, β-catenin, FAK-1, c-Myc,
Laminin 1, XIAP, p21, MELP, and 4E-BP1 present in this pathway were all up-regulated in tumorgraft forming tumors.
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necessary for successful engraftment of certain tumor
types e.g. leukemia [28,29], may better resemble the
human microenvironment, and could provide better
consistency in growth rates following implantation of
human tumor tissue into mice. However, in the context
of developing a panel of tumorgraft models across awide range of tumor types, the athymic nu/nu mouse
has proven a robust model.
The stage of the cancer at the time of acquisition has
an impact on a successful tumorgraft development. Only
10% of Stage I and II tumors successfully formed tumor-
grafts following implantation into mice; this is in con-
trast to the 43% take rate of tumor tissue from patients
Figure 6 Immune response pathway map enriched with genes down-regulated in the tumorgraft forming patient tumors. The
MetaCore™ pathway analysis suite (GeneGo-Thomson Reuters, St. Joseph, MI) identified a pathway map for an immune response involving
integrins in NK cell cytotoxicity that was enriched for several ligands down-regulated in tumors that did not form tumorgrafts (Target cell
denotes tumor cells).
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which was successfully propagated in the murine host.
Overall, ~75% of the 49 tumors that formed tumorgrafts
were from patients that were diagnosed either Stage III
or IV.
In this study, breast cancers had a take rate of only 6%
following subcutaneous implantation into mice. Dobro-
lecki et al [27] reported success in developing breast
cancer models by orthotopically implanting the breast
cancer tissue into the mammary fat pads of mice. While
more labor intensive than the subcutaneous model, an
orthotopic approach should be considered if there is
need for a tumorgraft model of a specific cancer that
cannot be established using the subcutaneous model.
An important conclusion from this study is that these
subcutaneous (predominantly ectopic with the exception
of melanomas) tumorgraft models recapitulate theexpression profiles of the original patient’s tumor within
its natural site of site of metastatic spread. This provides
some evidence that refutes the lack of relevance of the
subcutaneous model for drug discovery and develop-
ment, which may rather reflect the use of genetically
drifted in vitro cell lines in the classical xenograft con-
text. The primary value for any tumor model is to recap-
itulate the in-vivo malignant tissue state, and accurately
predict the efficacy of therapeutic agents in a timely and
cost-effective manner. In contrast with commonly used
animal models in which established human cancer cell
lines are injected subcutaneously and fail to accurately
predict human clinical trial results [8], this human
tumorgraft model system is more likely to be a success-
ful surrogate preclinical model for several reasons.
First, tumor bearing tissue fragments are transplanted
containing not only malignant cells, but also supporting
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Second, the transferred tumors include cells post en-
graftment retaining their essential cell to cell interac-
tions and relative state of differentiation as assessed by
their histological appearance. Third, because of the
high success rate in establishing not only 1st, but also
subsequent generation tumorgrafts, there is expansion
of the number of tumorgrafts available for testing and
the ability to verify retention of histological hallmarks
in a serial fashion. Fourth, assessment of tumor growth
is relatively straightforward given the subcutaneous
location of the xenografts. Finally, since portions
of tumors can be cryopreserved and successfully
engrafted post thawing, testing of therapeutic agents,
or combination therapies not originally considered, can
be studied with this experimental and scalable in vivo
model system.
In the era of molecularly targeted oncology agents, the
effective translation of results in the mouse model to the
clinic requires the genome of the tumorgraft model to
be high comparable to the original tumor [30]. Signifi-
cant changes in DNA fidelity or RNA expression levels
significantly diminish the translational value of a model.
Entire genome characterization of RNA expression ra-
ther, than a focused RT-PCR analysis of a select cohort
of genes [16], allows for the assessment of transcrip-
tome wide alterations and associated biological systems
that occur during the growth of the transplanted
human tumors.
The high Pearson correlations seen between the gen-
omes of the 24 pairs of tumorgraft and originating pa-
tient tumors implies that the donor tumor genome is
largely maintained in the tumorgraft model. Similarly,
genotypic fidelity has also recently been reported in a
panel of 25 human breast cancer tumorgrafts [27] and
on a smaller scale in secondary liver cancers using
quantitative PCR analysis of 21 genes related to onco-
genesis and cell cycle [15]. The lower Pearson correla-
tions observed in the gastrointestinal cancers could be
an artifact of the tissue harvest and the high levels of
digestive enzymes present in the patient tumors within
the gastrointestinal tract. High levels of RNases present
in pancreatic cancer are reported to complicate the ex-
traction of high quality RNA [31]. This finding high-
lights the importance of an optimized, rapid tissue
collection protocol, especially for genomic profiling. It
should be noted that poor RNA quality, for genomic
profiling does not necessarily impact the ability of the
tissue to form a viable tumorgraft. The high degree of
clustering by matched tumor/tumorgraft pairs (79%)
supports the high degree of similarity of the gen-
omes of the patient tumor and resulting mouse
tumorgraft even when the opportunity for RNA deg-
radation may occur.Genomic stability is an important characteristic to
consider prior to the long term use of a tumorgraft
model. The high correlation in gene expression across
four tumorgraft generations observed in this study and
similar findings of others [3,16,27,30] and absence of
drift in somatic mutations in known oncogenes, suggest
that the genomes of tumorgraft models are stable. Histo-
logical integrity of patient-derived tumorgrafts has also
been demonstrated for up to ten generations in
immune-compromised mice [4] and up to 30 passages
in mice without significant changes in growth and mor-
phological characteristics [15]. One study reported
tumorgraft models cultured in vivo for 10–12 genera-
tions before regenerating the models from earlier cryo-
preserved generations [3].
The role of somatic oncogene mutations in tumorigen-
esis, pathogenesis and disease progression can have a
profound influence on therapy [32]; mutations in onco-
genes RAS [33] and B-RAF [34] are commonly found in
a variety of cancers. Therefore it is imperative that such
mutations are maintained in the tumorgraft models. Al-
though only a few oncogenic mutations were observed,
those identified in the patient tumors were conserved in
the matching tumorgraft, consistent with other reports
[16] and consistent with known mutations in specific
tumor types [20,21].
There are a number of possible explanations for the
enrichment of canonical immune pathways within those
genes down-regulated in the tumorgrafts compared to
patient tumors. First, a loss of tumor cell immune path-
ways and proteins not necessary for growth and develop-
ment when transplanted from the immunecompetent
patient into the immunocompromised host. Second,
there is an intentional tumor tissue response to trans-
plantation to down regulate those genes responsible for
its immunogenic signature presented to the vestigial im-
mune defenses of the immunocompromised mouse. A
third explanation, and most likely, is that the gene ex-
pression changes are due to a loss of circulating human
immune cells which infiltrate and support tumor de-
velopment, when the tumor was transplanted from
the human into the mouse as earlier reported by
Neale et al [17].
In those patient tumors that formed tumorgrafts, up-
regulated genes show enrichment in pathways consid-
ered “usual suspects” in highly proliferative, late stage
tumors; these canonical pathways include cell cycle,
cytoskeletal remodeling, and those known drivers of
tumorigenesis WNT and AKT signaling [35-37]. These
same tumors were elevated for vascular endothelial
growth factor (VEGF). This increased level of VEGF in
the tumor could support the neovascularization of the
tumor once implanted into the mouse; Nisolle et al [38]
reported that the survival and growth of human
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lated with a high VEGF content. Transgenic expression
of VEGF into human islet cells followed by transplant
into the livers increased the rate of tissue revasculariza-
tion, survival and function [39]. A recent study demon-
strated the pre-treatment of human ovarian tissue with
VEGF and vitamin E prior to implantation into the
back muscle of immunodeficient mice demonstrated
enhanced growth, compared no pre-treatment of the
ovarian tissue [40].
The downregulation of immunological pathways in the
tumors that formed tumors would suggest that loss of
immune pathways is a mark of late stage tumors and
provides a selective advantage supporting the establish-
ment of the tumors in a foreign host or location. This
downregulation of immunological pathways could be a
reflection of the loss of expression signature of patient
immune infiltrating cells [17]. Of particular note is the
downregulation of natural killer (NK) cell ligands, as
identified as a pathway enriched for genes down-
regulated in tumors that formed tumorgrafts compared
to those tumors that failed to form tumorgrafts (Fig-
ure 4B). Although athymic nu/nu mice cannot generate
mature T lymphocytes, they maintain the ability to
mount a response to T-independent antigens [41] and
do produce NK cells as a component of their vestigial
immune system. The downregulation of the NK ligands
may therefore promote human tumor development in
immune compromised mice. While there is little evi-
dence demonstrating the interaction of human integrins
and murine NK receptors, Kanwar et al reports interspe-
cies cross-talk via the demonstration that the ectopic ex-
pression of human intercellular cell adhesion molecule-1
(ICAM-1) in mouse EL-4 tumors inhibited in vivo tumor
growth [42]. The mechanisms of NK cell recognition of
self and immunosurveillance in both mouse and humans
are complex and involve numerous receptors that
recognize many cell surface ligands [43]. Experimental
evidence clearly supports the view that murine NK cells
can inhibit human tumor cell development and metasta-
sis both in vitro and in vivo [44-50].
This study reports the development of a series of
tumorgraft models, representing a broad spectrum of
cancer types, derived from molecularly characterized
fresh patient tumor tissue. The genomes of these
tumorgraft models exhibit a high degree of correlation
to their originating patient tumors which is maintained
over multiple generations of in vivo passages. The loss
of immune function pathways and gain of cell prolif-
eration pathways suggests a logical selective pressure
for certain tumors to form tumorgrafts, which could
be prescreened in future studies to identify those most
likely to develop into useful preclinical models for
translational studies.Conclusions
The maintenance of the genome in the tumorgraft, from
the human to murine host, supports the concept that
tumorgraft models can provide an invaluable and robust
tool in the evaluation of precision medicine methodolo-
gies and novel treatment strategies prior to use in clin-
ical trials. An important point is that a subcutaneous
primary patient tumorgraft models can recapitulate the
expression profiles of the original “orthotopic” disease in
the human and allow for reasonably high-throughput
preclinical screens for drug efficacy. These models may
therefore be useful in reducing the rate of attrition in
drug development that has been in part been attributed
to the use of the classical cell line xenografts.
Additional files
Additional file 1: Table S1. The spreadsheet contains the results of
the differential gene expression analysis comparing each patient’s
tumor with the paired tumorgraft. This file contains two spreadsheet
tabs. The first tab displays the 17 gene probesets up-regulated in
tumorgrafts (Group 2, column C) relative to the originating patient
tumors (Group 1, column B), and the second tab displays the 395 gene
probes down-regulated. The official gene name, mean normalized
intensity in Groups 1 and 2, the associated fold-change in gene
expression (Group 2/Group 1), the calculated pairwise t-test statistic, the
corresponding p-value, the False Discovery Rate, and the Affymetrix
probeset identifiers are shown.
Additional file 2: Table S2. The spreadsheet contains the results of
the differential gene expression analysis comparing the patient
tumors that successfully developed tumorgrafts with those that
did not. This file contains two spreadsheet tabs. The first sheet displays
the 491 gene probesets up regulated in the tumors that successfully
formed tumorgrafts (Group 2, column C) relative to those that did not
(Group 1, column B) and the second sheet displays the 691 gene probes
down regulated. The official gene name, mean normalized intensity in
Groups 1 and 2, the associated fold-change in gene expression
(Group 2/Group 1), the calculated student’s t-test statistic, the
corresponding p-value, the False Discovery Rate, and the Affymetrix
probeset identifiers are shown.
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